Immunoscore®, IS2C402Dispositif médical de Diagnostic in Vitro pour aider au pronostic des patients atteints de cancer localisé du colon Veracyte SAS (France)Lire attentivement les instructions fournies dans le document dédié à la préparation de l’échantillon disponible en ligne:www.veracyte.com

IMMUNOSCORE® is included in the ESMO Clinical Practice Guidelines (ESMO 2020 Guidelines as well as PAN-Asian adapted ESMO Guidelines 2021 for Localised Colon Cancer)

Ref.: ICO03-000-057 v12 I © 2021 Veracyte, Inc. and affiliates. All rights reserved. Veracyte and HalioDx are trademarks of Veracyte, Inc. and its affiliates. Immunoscore is a trademark of Inserm and used under license I Design: ATCG Partners - Sophie Geider - Photography Adobe

Follow us

REFERENCE PUBLICATIONS

Pagès F, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018 May 26;391(10135):2128-2139.

Galon J, et al. Immunoscore clinical utility to identify good prognostic colon cancer stage II patients with high-risk clinico-pathological features for whom adjuvant treatment may be avoided. J Clin Oncol. 2019. 37:4_suppl, 487-487.

Sinicrope, et al. Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer. JNCI Cancer Spectr. 2020 Apr 5;4(3):pkaa023.

Pagès F, et al. Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study. Ann Oncol. 2020 Jul;31(7):921-929.

Mlecnik B, et al. Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. J Clin Oncol. 2020 Nov 1;38(31):3638-3651.

IMMUNITY ASSESSED, TREATMENT PERSONALIZEDGuide your therapeutic strategy and patient discussion with accurate information based on immune response

Contact usVeracyte Labs FR 163 Avenue de Luminy - 13009 Marseille - FRANCE P +33 (0) 4 91 29 30 90

F +33 (0) 4 91 29 30 99

Veracyte Labs VA 737 N 5th St, 6th Floor - Richmond, VA 23219 - USA P + 1 (804) 944-2000F +1 (804) 533-1504

www.veracyte.com

The IMMUNOSCORE® and its performance characteristics were determined by Veracyte. This test has not been cleared or approved by the FDA.

Clinico-pathological parameters plus IMMUNOSCORE®

Mucinous (colloid)MSISex

IMMUNOSCORE(High, Low)

LVI/PNIAJCC/UICC

TNM stage

Di�erentiation

47%of prognosis

is explained by IMMUNOSCORE®

By providing an accurate measurement of T lymphocyte infiltration into the tumor, IMMUNOSCORE® gives healthcare providers insight into the risk of relapse.

Designed to deliver critical information to guide chemotherapy decision-making, IMMUNOSCORE®* can be used in Stage II localized colon cancer to help physicians identify patients who may be spared adjuvant chemotherapy, and in stage III colon cancer to better inform on optimal FOLFOX treatment duration.Recently included within ESMO guidelines, IMMUNOSCORE® predicts the risk of relapse in patients with localized colon cancer.

IMMUNE INFILTRATIONLOCALIZED COLON CANCER PATIENTS RISK OF RELAPSE

Hig

h infiltration of T lympho

cytes

Low infiltration of T lymp

hocytes

IMMUNOSCORE®

LOW

IMMUNOSCORE® HIGH

HIGHRISK

LOWRISK

Add resolution to your traditional risk assessment tools

Pagès F et al. The Lancet 2018

Validated in a large international study conducted on more than 2500 Stage I-III colon cancer patients (Pagès et al, The Lancet 2018), IMMUNOSCORE® was demonstrated to be a powerful and independent prognostic factor for patient survival, providing the greatest contribution to patient prognostication of all assessed factors.

*CE-IVD for European Community countries, performed in CLIA certified laboratory for the US

10 working days after receipt of

specimen

Pathologylab

Patientpost resection

surgery

Tumor block orunstained slides

ComputeIMMUNOSCORE®

Veracytelabs

Stain & Scan Slides

Report IMMUNOSCORE®

results

An IMMUNOSCORE® Low means there are few T-cells present to fight the cancer, indicating a high risk of relapse. Conversely, an IMMUNOSCORE® High means there is high infiltration of T lymphocytes, indicating a lower risk of relapse.

How can IMMUNOSCORE® help patient with localized colon cancer management?

Introducing IMMUNOSCORE® into routine clinical practice at diagnosis gives oncologists access to precision medicine for improving cancer management outcomes and can help in:

Assessing patient’s recurrence risk

Providing greater prognostic value than traditional measurements

Guiding treatment decision and improves patients management

A Clear Way ForwardIMMUNOSCORE® can help patients and clinicians find more diagnostic clarity and get the actionable results needed to make better treatment decisions.

Stage II Colon Cancer

IMMUNOSCORE® can identify a large subset of patients (70%) that are classified as high-risk by TNM staging but whose actual risk of relapse is similar to that of low-risk patients. These patients can potentially be spared adjuvant chemotherapy and the associated toxicities.

70% of patients classified as clinically high risk

actually have the same risk of relapse as low-

risk patients when IMMUNOSCORE is High.

Stage III Colon Cancer

IMMUNOSCORE® informs about the optimal duration of FOLFOX treatment whatever the clinical risk, maximizing the benefit-risk balance by avoiding unnecessary exposure to chemotherapy associated toxicities.

50%

of patients benefit the most from full

chemotherapy duration

IMMUNOSCORE® WORKFLOWIMMUNOSCORE® is available as a full service solution

(performed at Veracyte CLIA laboratories).

Clinico-pathological parameters plus IMMUNOSCORE®

Mucinous (colloid)MSISex

IMMUNOSCORE(High, Low)

LVI/PNIAJCC/UICC

TNM stage

Di�erentiation

47%of prognosis

is explained by IMMUNOSCORE®

By providing an accurate measurement of T lymphocyte infiltration into the tumor, IMMUNOSCORE® gives healthcare providers insight into the risk of relapse.

Designed to deliver critical information to guide chemotherapy decision-making, IMMUNOSCORE®* can be used in Stage II localized colon cancer to help physicians identify patients who may be spared adjuvant chemotherapy, and in stage III colon cancer to better inform on optimal FOLFOX treatment duration.Recently included within ESMO guidelines, IMMUNOSCORE® predicts the risk of relapse in patients with localized colon cancer.

IMMUNE INFILTRATIONLOCALIZED COLON CANCER PATIENTS RISK OF RELAPSE

Hig

h infiltration of T lympho

cytes

Low infiltration of T lymp

hocytes

IMMUNOSCORE®

LOW

IMMUNOSCORE® HIGH

HIGHRISK

LOWRISK

Add resolution to your traditional risk assessment tools

Pagès F et al. The Lancet 2018

Validated in a large international study conducted on more than 2500 Stage I-III colon cancer patients (Pagès et al, The Lancet 2018), IMMUNOSCORE® was demonstrated to be a powerful and independent prognostic factor for patient survival, providing the greatest contribution to patient prognostication of all assessed factors.

*CE-IVD for European Community countries, performed in CLIA certified laboratory for the US

10 working days after receipt of

specimen

Pathologylab

Patientpost resection

surgery

Tumor block orunstained slides

ComputeIMMUNOSCORE®

Veracytelabs

Stain & Scan Slides

Report IMMUNOSCORE®

results

An IMMUNOSCORE® Low means there are few T-cells present to fight the cancer, indicating a high risk of relapse. Conversely, an IMMUNOSCORE® High means there is high infiltration of T lymphocytes, indicating a lower risk of relapse.

How can IMMUNOSCORE® help patient with localized colon cancer management?

Introducing IMMUNOSCORE® into routine clinical practice at diagnosis gives oncologists access to precision medicine for improving cancer management outcomes and can help in:

Assessing patient’s recurrence risk

Providing greater prognostic value than traditional measurements

Guiding treatment decision and improves patients management

A Clear Way ForwardIMMUNOSCORE® can help patients and clinicians find more diagnostic clarity and get the actionable results needed to make better treatment decisions.

Stage II Colon Cancer

IMMUNOSCORE® can identify a large subset of patients (70%) that are classified as high-risk by TNM staging but whose actual risk of relapse is similar to that of low-risk patients. These patients can potentially be spared adjuvant chemotherapy and the associated toxicities.

70% of patients classified as clinically high risk

actually have the same risk of relapse as low-

risk patients when IMMUNOSCORE is High.

Stage III Colon Cancer

IMMUNOSCORE® informs about the optimal duration of FOLFOX treatment whatever the clinical risk, maximizing the benefit-risk balance by avoiding unnecessary exposure to chemotherapy associated toxicities.

50%

of patients benefit the most from full

chemotherapy duration

IMMUNOSCORE® WORKFLOWIMMUNOSCORE® is available as a full service solution

(performed at Veracyte CLIA laboratories).

Immunoscore®, IS2C402Dispositif médical de Diagnostic in Vitro pour aider au pronostic des patients atteints de cancer localisé du colon Veracyte SAS (France)Lire attentivement les instructions fournies dans le document dédié à la préparation de l’échantillon disponible en ligne:www.veracyte.com

IMMUNOSCORE® is included in the ESMO Clinical Practice Guidelines (ESMO 2020 Guidelines as well as PAN-Asian adapted ESMO Guidelines 2021 for Localised Colon Cancer)

Ref.: ICO03-000-057 v12 I © 2021 Veracyte, Inc. and affiliates. All rights reserved. Veracyte and HalioDx are trademarks of Veracyte, Inc. and its affiliates. Immunoscore is a trademark of Inserm and used under license I Design: ATCG Partners - Sophie Geider - Photography Adobe

Follow us

REFERENCE PUBLICATIONS

Pagès F, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018 May 26;391(10135):2128-2139.

Galon J, et al. Immunoscore clinical utility to identify good prognostic colon cancer stage II patients with high-risk clinico-pathological features for whom adjuvant treatment may be avoided. J Clin Oncol. 2019. 37:4_suppl, 487-487.

Sinicrope, et al. Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer. JNCI Cancer Spectr. 2020 Apr 5;4(3):pkaa023.

Pagès F, et al. Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study. Ann Oncol. 2020 Jul;31(7):921-929.

Mlecnik B, et al. Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. J Clin Oncol. 2020 Nov 1;38(31):3638-3651.

IMMUNITY ASSESSED, TREATMENT PERSONALIZEDGuide your therapeutic strategy and patient discussion with accurate information based on immune response

Contact usVeracyte Labs FR 163 Avenue de Luminy - 13009 Marseille - FRANCE P +33 (0) 4 91 29 30 90

F +33 (0) 4 91 29 30 99

Veracyte Labs VA 737 N 5th St, 6th Floor - Richmond, VA 23219 - USA P + 1 (804) 944-2000F +1 (804) 533-1504

www.veracyte.com

The IMMUNOSCORE® and its performance characteristics were determined by Veracyte. This test has not been cleared or approved by the FDA.